We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This PAR covers the assessment of an application to reclassify Calci-D chewable tablets from Prescription Only Medicine (POM) to Pharmacy (P) medicine.
Public Assessment Report (PAR) reviewing available safety data for topical steroid withdrawal reactions, which have been associated with topical corticosteroids.
The Commission on Human Medicines (CHM) has reviewed the available safety data for the use of the macrolide antibiotics erythromycin, clarithromycin and azithromycin during pregnancy.
This PAR covers the assessment of an application to reclassify Nasacort Allergy Relief for Adults 55 micrograms/dose, nasal spray, suspension from Pharmacy (P) medicine to General Sales List.
This PAR covers the assessment of an application to reclassify Almerg 180mg film-coated tablets from Prescription Only Medicine (POM) to Pharmacy (P) medicine.
The Commission on Human Medicines (CHM) has concluded that the risk of vCJD cases arising from the use of UK plasma for the manufacture of immunoglobulin medicinal products would be negligible.
A regulatory approach for updating authorised coronavirus vaccines should mutations at any time make them less efficacious due to insufficient cross-reactivity.
The MHRA has developed, and now has in place, a four-stranded approach to vigilance, which is summarised in this report.
The Commission on Human Medicines has reviewed the available safety data for epilepsy medicines during pregnancy.
This PAR covers the assessment of an application to reclassify Allevia 120mg tablets from Prescription Only Medicine (POM) to General Sales List (GSL).
This PAR covers the assessment of an application to reclassify Benacort Hayfever Relief for Adults 64 micrograms, nasal spray from Prescription Only Medicine (POM) to General Sales (GSL).
Medicines and Healthcare products Regulatory Agency (MHRA) good manufacturing practice (GMP) deficiencies since April 2010.
Public Assessment Report (PAR) discussing new risk minimisation measures which are being put into place for certain over-the-counter (OTC) stimulant laxatives.
Details and statistics on the import of unlicensed medicines from March 2014 onwards.
MHRA conducted research into the obstacles to good evidence being provided in consultation responses.
The final report from the Scottish independent review of the use, safety and efficacy of transvaginal mesh implants.
Good clinical practice (GCP) referrals received by the MHRA for 2011 to 2016.
An interim report from the NHS England-led vaginal mesh working group on mesh used to treat stress urinary incontinence (SUI) and pelvic organ prolapse.
An interim report from the Scottish independent review of the use, safety and efficacy of transvaginal mesh implants.
This report makes recommendations on whether to regulate practitioners of herbal medicine and the products they use to keep the public safe.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.